Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun 5;19(1):164.
doi: 10.1186/s12957-021-02276-5.

Feasibility and outcomes of cytoreductive surgery and HIPEC for peritoneal surface malignancies in low- and middle-income countries: a single-center experience of 232 cases

Suryanarayana Deo  1 , Mukurdipi Ray  2 , Babul Bansal  2 , Sandeep Bhoriwal  2 , Sushma Bhatnagar  3 , Rakesh Garg  3 , Nishkarsh Gupta  3 , Atul Sharma  4 , Lalit Kumar  4 , Sanjay Thulkar  5 , Ekta Dhamija  5 , Sandeep Mathur  6 , Prasenjit Das  6
Affiliations

Feasibility and outcomes of cytoreductive surgery and HIPEC for peritoneal surface malignancies in low- and middle-income countries: a single-center experience of 232 cases

Suryanarayana Deo et al. World J Surg Oncol. .

Abstract

Background: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) has recently emerged as a viable management option for peritoneal surface malignancy (PSM). CRS and HIPEC is a complex, multidisciplinary and resource-intensive surgical procedure. It has a steep learning curve and is associated with significant morbidity and mortality. The expertise is mostly limited to few dedicated high-volume centers located in developed countries. We present a single institutional experience of 232 cases of CRS and HIPEC performed at a tertiary care cancer center in a low- and middle-income country (LMIC).

Methods: A multidisciplinary PSM program was initiated in 2015 at a high-volume public-sector tertiary care cancer center in North India catering largely to patients belonging to low- and middle-income groups. Perioperative protocols were developed, and a prospective structured database was created to capture data. All patients undergoing CRS and HIPEC between January 2015 and December 2020 were identified, and the data was retrospectively analyzed for clinical spectrum, surgical details, and perioperative morbidity and mortality.

Results: Two hundred and thirty-two patients underwent CRS and HIPEC during the study period. Epithelial ovarian carcinoma (56.5%) was the most common malignancy treated, followed by pseudomyxoma peritonei (18.5%), colorectal carcinoma (13.4%), and malignant mesothelioma (5.6%). Optimal CRS could be achieved in 94.4% of patients. Cisplatin and mitomycin were the most common drugs used for HIPEC. A total of 28.0% of patients had morbidity including deep vein thrombosis, subacute intestinal obstruction, sepsis, burst abdomen, lymphocele, urinoma, acute renal failure, and enterocutaneous fistula. The overall treatment-related mortality was 3.5%.

Conclusions: Results of the current study indicate that it is feasible to establish a successful CRS and HIPEC program for PSM in government-funded hospitals in LMIC facing resource constraints. The most common indication for CRS and HIPEC were carcinoma of the ovary followed by pseudomyxoma peritonei and colorectal carcinoma. Overall morbidity and mortality in the current series are comparable to global standards, reported from high-income countries. A protocol-based multidisciplinary team approach, optimal patient selection, and surgical expertise can help achieve optimal outcomes in government-funded hospitals in LMIC.

Keywords: Cytoreductive surgery; HIPEC; LMIC; Peritoneal surface malignancy; Tertiary care center.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
HIPEC technique. a Suspension of abdominal wall edges to OmnitractTM retractor to create a Coliseum. b SunchipTM machine. c Coliseum covered with Steri-DrapeTM (semi-open)
Fig. 2
Fig. 2
Year-wise trends of CRS and HIPEC
See this image and copyright information in PMC

References

    1. Sugarbaker PH. Management of peritoneal-surface malignancy: the surgeon’s role. Langenbeck's Arch Surg. 1999;384(6):576–587. doi: 10.1007/s004230050246. - DOI - PubMed
    1. Neuwirth MG, Alexander HR, Karakousis GC. Then and now: cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC), a historical perspective. J Gastrointest Oncol. 2016;7(1):18–28. doi: 10.3978/j.issn.2078-6891.2015.106. - DOI - PMC - PubMed
    1. Kusamura S, Baratti D, Deraco M. Multidimensional analysis of the learning curve for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal surface malignancies. Ann Surg. 2012;255(2):348–356. doi: 10.1097/SLA.0b013e3182436c28. - DOI - PubMed
    1. International PSOGI-recommendations for the management of peritoneal metastases. In: PSOGI. http://www.psogi.com/psogi/international-recommendations-for-the-managem.... Accessed 30 Apr 2020
    1. Low RN, Barone RM, Lucero J. Comparison of MRI and CT for predicting the peritoneal cancer index (PCI) preoperatively in patients being considered for cytoreductive surgical procedures. Ann Surg Oncol. 2015;22(5):1708–1715. doi: 10.1245/s10434-014-4041-7. - DOI - PubMed